Corneal Cross-Linking: Current USA Status: Report From the Cornea Society
AffiliationUniv Arizona, Dept Ophthalmol & Vis Sci
MetadataShow full item record
PublisherLIPPINCOTT WILLIAMS & WILKINS
CitationBelin, M. W., Lim, L., Rajpal, R. K., Hafezi, F., Gomes, J. A., & Cochener, B. (2018). Corneal Cross-Linking: Current USA StatusReport From the Cornea Society. Cornea, 37(10), 1218-1225.
RightsCopyright © 2018 The Cornea Society. Published byWolters Kluwer Health, Inc.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractThe initial published clinical report on riboflavin/ultraviolet A corneal cross-linking (CXL) for treatment of progressive keratoconus dates back to 2003. CXL has since then been widely used outside the United States for treatment of progressive keratoconus and post-laser in situ keratomileusis ectasia. The Food and Drug Administration (FDA) approved Avedro Inc.'s corneal cross-linking system (KXL) for treatment of patients with progressive keratoconus and post-laser in situ keratomileusis ectasia in April 2016. The procedure is not currently approved for stable keratoconus. There are 2 FDA-approved topical ophthalmic solutions for use in CXL. Riboflavin 5'-phosphate in 20% dextran ophthalmic solution 0.146% (Photrexa Viscous) and Riboflavin 5'-phosphate ophthalmic solution 0.146% (Photrexa) are intended for use with the KXL system. Photrexa Viscous is used in all CXL procedures, whereas Photrexa is indicated for use when the corneal stroma is thinner than 400 µm after completion of the Photrexa Viscous induction period. The FDA-approved procedure using the Dresden protocol (UV-A, 3 mW/cm for 30 min) induces cytologic and morphologic changes in the anterior 250 to 300 µm of the corneal stroma. It has been believed that a minimum thickness of 400 μm was necessary to protect the corneal endothelium from potential damage. The CXL procedure using the standard Dresden protocol is established as the gold standard for treatment of progressive keratoconus. CXL treatment is indicated for a list of conditions ranging from corneal ectasia to infectious keratitis. Newer protocols, treatment regimens, and expanded indications will require further refinements, investigations, and long-term studies.
Note12 month embargo; originally published 1 October 2018.
VersionFinal accepted manuscript
- Intraoperative corneal thickness measurements during corneal collagen cross-linking with isotonic riboflavin solution without dextran in corneal ectasia.
- Authors: Cınar Y, Cingü AK, Sahin A, Türkcü FM, Yüksel H, Caca I
- Issue date: 2014 Mar
- Current perspectives on corneal collagen crosslinking (CXL).
- Authors: Subasinghe SK, Ogbuehi KC, Dias GJ
- Issue date: 2018 Aug
- Comparison of the Conventional Dresden Protocol and Accelerated Protocol With Higher Ultraviolet Intensity in Corneal Collagen Cross-Linking for Keratoconus.
- Authors: Choi M, Kim J, Kim EK, Seo KY, Kim TI
- Issue date: 2017 May
- Newer protocols and future in collagen cross-linking.
- Authors: Cummings AB, McQuaid R, Mrochen M
- Issue date: 2013 Aug
- The theory and art of corneal cross-linking.
- Authors: McQuaid R, Cummings AB, Mrochen M
- Issue date: 2013 Aug